Enfortumab Vedotin
Antibody–drug conjugate
Evidence outlook
Approved: Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Non-Small Cell Lung Cancer · Phase 1/2 · investigational in the US
Also approved (3)
- PADCEV (enfortumab vedotin) for adult patients with locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD-1/PD-L1 inhibitor
- Muscle invasive bladder cancer (MIBC) Padcev, in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. Unresectable or metastatic urothelial cancer Padcev, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. Locally...
- Treatment of unresectable urothelial carcinoma that has progressed after cancer chemotherapy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03474107 NCT03474107 · Ureteral Cancer, Urothelial Cancer, Bladder Cancer The trial was large and randomized, with chemotherapy as an active comparator, and its hard clinical primary endpoint of overall survival was met (12.88 vs 8.97 months; p=0.00142; hazard ratio 0.702). However, treatment was open-label rather than double-blinded, so the evidence is rated moderate despite the favorable result. Registry: NCT03474107 | 3 | Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)) 2020-07-15 | Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) | Partial signal | link ↗ |
View 4 more trials
KEYNOTE-B15 NCT04700124 · Bladder Cancer This was a large randomized phase 3 trial against standard cisplatin-based chemotherapy, and the published primary result showed significantly longer event-free survival (hazard ratio 0.53, p<0.001). It was open-label, so patients and doctors knew the assigned treatment; recurrence was read by a blinded independent central review, but the event-free survival measure also counts events such as failure to undergo surgery. Registry: NCT04700124 | 3 | Event-Free Survival (EFS) (Up to ~68 months) 2025-10-27 | Results not posted; external-source review pending | Partial signal | link ↗ |
NCT03924895 NCT03924895 · Bladder Cancer Participants were randomized to open-label enfortumab vedotin plus pembrolizumab and surgery or surgery alone; the primary event-free survival endpoint was met, with a hazard ratio of 0.40 (95% CI 0.28–0.57; p<0.0001). The open-label design and absence of a reported sample-size/power calculation support a moderate rather than strong evidence grade despite the large randomized comparison. Registry: NCT03924895 | 3 | Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone (Up to approximately 53 months) 2025-06-06 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT03219333 NCT03219333 · Bladder Cancer The study was open-label and single-arm, with no placebo or active comparator; 219 patients were enrolled and 214 received treatment. Its primary endpoint was an objective imaging-based response measure, reported as 44% in Cohort 1 and 51.7% in Cohort 2, but without a randomized comparison, so the results provide limited controlled evidence of enfortumab vedotin's effectiveness. Registry: NCT03219333 | 2 | Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)) 2020-10-27 | Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | Weak signal | link ↗ |
NCT03288545 NCT03288545 · Carcinoma Registry: NCT03288545 | 1/2 | Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only) (Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.); Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only) (Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.); Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only) (Up to 3 years); Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only) (Up to approximately 5 months) 2026-02-20 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (42)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2/3 (1)
What this study did
Competitive landscape
Other Nectin-4 drugs
Notiretatug rezetecan, Sutantatug envedotin, Zelenectide pevedotin, IPH4502, LY4052031. Compare all 6 Nectin-4 drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin: this drug | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3(overall) | Antibody–drug conjugate | Nectin-4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| Zelenectide Pevedotin | Phase 2(overall) | Peptide | Nectin-4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(58 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Enfortumab Vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (23)
January 2027 (2)
February 2027 (1)
What to watch
March 2027 (1)
What to watch
April 2027 (2)
May 2027 (1)
What to watch
June 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
September 2027 (3)
What to watch
What to watch
What to watch
October 2027 (2)
What to watch
What to watch
November 2027 (4)
What to watch
What to watch
What to watch
What to watch
December 2027 (1)
What to watch
2028 (17)
January 2028 (2)
March 2028 (4)
What to watch
What to watch
What to watch
What to watch
June 2028 (3)
What to watch
What to watch
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (2)
September 2028 (3)
What to watch
What to watch
What to watch
2029 (7)
February 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
September 2029 (2)
October 2029 (1)
What to watch
2030 (5)
March 2030 (1)
What to watch
April 2030 (1)
What to watch
May 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (2)
2034 (1)
November 2034 (1)
What to watch
Regulatory and conference events
(10)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent